The perception of GLP-1s — and the people who use them — is getting better, but work still must be done to avoid stigma.

Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.

Parents in Wiltshire might want to put the chocolates on a high shelf and keep an eye on the fizzy drinks this Christmas, ...

Research indicates low-carb diets may enhance appetite regulation and reduce food cues in women with lipedema, offering a ...

Danish pharma major Novo Nordisk has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide and semaglutide) injection, to be used ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

The telehealth service now provides a digital weight management programme featuring genuine prescription GLP-1 agonist drugs.

This has been a well-established fact: current food culture across the world has much to do with obesity becoming a more and ...

Novo Nordisk’s NDA filing for CagriSema positions the first fixed-dose amylin–GLP-1 combination as a potential ...

HONG KONG SAR - Media OutReach Newswire - 19 December 2025 - Amid a global surge in demand for the weight-management ingredient GLP-1, the Hong Kong market has ...

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S.